A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.

Timeline

Start

2022-03-24

Primary completion

2024-03

Completion

2024-12

Publications

• Yang Y, Tang J, Wu Z, Zhang J, Liu D, Fan J, Wu G, Zhang T, Xue J. Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. Cancer Pathog Ther. 2025 Dec 19;4(4):297-309. doi: 10.1016/j.cpt.2025.12.002. eCollection 2026 Jul.

Drugs

Indications